Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination With EBRT
Authors:
- 12 June 2025
- journal article
- review article
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 35 (3) , 463-473
Abstract
No abstract availableKeywords
Funding Information
- Prostate Cancer Foundation (22TACT01, 101172722, 101172788)
This publication has 82 references indexed in Scilit:
- Optimizing treatment for Gleason 10 prostate cancer: radiation dose escalation and 68Ga-PSMA-PET/CT stagingStrahlentherapie und Onkologie, 2025
- Implementation of PET/CT in radiation oncology—a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation OncologyStrahlentherapie und Onkologie, 2024
- Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate CancerJAMA Network Open, 2023
- Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga‐PSMA‐PET/CT in prostate cancer patients candidate to definitive radiotherapyThe Prostate, 2021
- 225Ac‐PSMA‐617‐targeted alpha therapy for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysisThe Prostate, 2021
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerJAMA Oncology, 2020
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate CancerJAMA Oncology, 2019
- The EANM practice guidelines for bone scintigraphyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- 18F-NaF PET/CT: EANM procedure guidelines for bone imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012